Key result
PAR-1 antagonists target thrombin-mediated platelet activation to potentially provide comprehensive antithrombotic effects in ischemic heart disease.
Answers are grounded in this paper and cite their sources.
This review summarizes the pathophysiology of atherothrombosis and the clinical data supporting the use of PAR-1 antagonists to prevent thrombosis.
Platelets contribute fundamentally to ischemic heart disease, and antiplatelet therapy has been critical to reducing acute thrombotic complications of atherosclerotic disease. Thrombin, by acting on protease activated receptors (PAR), is one of the most potent platelet activators. PAR-1 antagonists may therefore provide more comprehensive antithrombotic effects. We review the pathophysiology of atherothrombosis, platelet activation by thrombin, the role of platelet protease activated receptors (PAR), and the clinical data supporting their use.
No takes yet. Share an insight, caveat, or question.
Wallace et al. (2013) conducted a review in Ischemic heart disease and atherothrombosis. PAR-1 antagonists was evaluated. PAR-1 antagonists target thrombin-mediated platelet activation to potentially provide comprehensive antithrombotic effects in ischemic heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: